prothrombin levels and an increased risk for venous thrombosis (5, 8) . MTHFR A1298C and MTHFR C677T point mutations result in reduced enzyme activity that leads to elevated homocysteine concentrations and decreased folate concentration in plasma, which may represent important risk factors in thromboembolic diseases (9) . We conducted this study to determine the prevalence of FV Leiden, FV Hong Kong, FII G20210A, MTHFR C677T, and MTHFR A1298C in Turkish patients with a history of venous thromboembolic events and healthy control subjects, as well as to name unknown nucleotide variations in factor V, factor II, and MTHFR genes.
METHODS
The patient group consisted of a total 270 unrelated cases, 84 men and 186 women, who presented acute clinical symptoms of DVT, such as pain, edema, and venous distention. The DVT diagnosis was made clinically and confirmed by color Doppler ultrasonography. In a total of 270 patients, 131 patients had spontaneous DVT and a family history. Sixty of the remaining patients had DVT during pregnancy or in the postpartum period. Fifty-seven patients were diagnosed after a trauma and 22 in the postoperative period. Control samples were selected from 114 healthy individuals with nonvascular diseases and a nonthrombosis history. Informed consent forms were fulfilled and signed by all patients and controls. Na 2 EDTA anticoagulated peripheral blood samples were collected from both patients and controls. Genomic DNAs were isolated from blood leukocytes with a modified salting-out procedure (10) . The purity and concentration of isolated DNA were determined by spectrophotometer and observed with 0.8% agarose gel electrophoresis. The primer selection, polymerase chain reactions, and DNA analyses were carried out with slight modifications described in previous studies (2, 5, 6) . All individuals were subject to DNA analyses for FV Leiden, FV Hong Kong, FII G20210A, MTHFR C677T, and MTHFR A1298C mutations. Singlestrand conformation analysis (SSCA) was conducted using the primers selected for restriction enzyme analysis, and electrophoreses were performed on 37.5:1 native acrylamide gels using the appropriate gel concentrations and electrophoresis conditions for each region. Statistical analyses were performed using χ 2 -compared baseline characteristics of cases and control individuals. The crude odds ratios and confidential intervals were estimated in patient and control groups.
RESULTS
A total number of 270 unrelated patients, 84 men and 186 women, and 114 healthy individuals were subjected to restriction enzyme analysis and SSCA analyses. The homozygous and heterozygous states of each mutation and their combinations were calculated to determine the genotype frequencies. The genotype frequencies of the mutations are given in Table 1 . The outcome showed that FV Leiden was found in 76 (28.3%) patients and 4 (3.5%) controls, and FII G20210A was found in 23 (8.6%) patients and 2 (1.8%) healthy controls. The MTHFR C677T mutation was detected in 134 patients and 45 controls and MTHFR A1298C in 170 patients and 64 controls. The calculated genotype frequencies for FV Leiden and FII G20210A mutations differed significantly between patient and control groups. MTHFR C677T and A1298C mutations were equally distributed between patient and control groups. The substitution at position 1090 of factor V gene was detected in 2 patients and in none of the control subjects. The genotype frequencies of these mutations in conjunction with at least 1 of the other variations were also calculated, and the results are summarized in Table 2 . The combinations of FV Leiden with FII G20210A were not found to affect the prevalence of thrombosis in statistical analyses. In our study, the combination of FV Leiden with MTHFR C677T was observed in 35 patients and no controls, and with MTHFR A1298C, it was observed in 46 patients and 4 controls. The mobility differences of FV Leiden, FV Hong Kong, FII G20210A, MTHFR C677T, and MTHFR A1298C mutations in their homozygous, heterozygous, and compound heterozygous states were carefully assessed using the SSCA technique. The results showed that all cases, which were found positive for the mutations mentioned previously here, gave a significant pattern, but unfortunately, there were no other variations detectable with the optimized conditions.
DISCUSSION
In this study, the differences in prevalence of genetic risk factors for thrombosis in both patient and control groups in the Turkish population were studied. The observed genotype frequencies of FV Leiden and FII G20210A mutations were found to be 28.3% and 8.6%, respectively, pointing to a significant association between these alleles and thrombosis. These findings were in concordance with the study published by Gurgey et al (11) . We observed higher frequencies for FV Leiden and FII G20210A mutations in Turkish thrombosis patients compared with other studies in other populations (12) . Although Grossman et al concluded that FV Leiden mutation frequencies were similar in both patient and control groups, recent research data with more detailed analyses contradict their findings (13) . We observed that the genotypes MTHFR C677T and A1298C do not appear to be important risk factors for thromboembolic disorders when present alone. The combination of MTHFR mutations with FV Leiden increased thrombosis risks according to statistical analyses and the clinical findings of these patients. Lu et al showed that MTHFR C677T was a common mutation in the Chinese population, thus correlating with our findings. In their study, FV Leiden and FII G20210A mutations were determined as risk factors (14) . FV Leiden and FII G20210A mutations were also found to be relevant risk factors partly for pulmonary vein thrombosis (15) . Chan et al determined a genetic abnormality at exon 7 (Arg306) of the FV gene, named FV Hong Kong, and found 2 positive cases in the thrombosis group and only 1 in the control group in that study (6) . We could not observe an abnormal DNA pattern/variation using selected primers for FV Leiden, FV Hong Kong, FII G20210A, MTHFR C677T, and MTHFR A1298C mutations by SSCA and DNA sequencing analysis. The thrombosis mutations that we screened in this study make up 25% to 50% of venous thromboembolism patients (16, 17) . Our aim focused on determining other thrombosis factor genes and gene polymorphism-gene polymorphism interactions that play a role in families with thrombosis history. Associations between inherited abnormalities and thromboembolic disorders will be helpful for diagnosis and treatment of thrombosis.
